Hyperglycemia in pasireotide-treated patients with acromegaly and its treatment.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

8 citing papers in PubMed.

1. Safety and tolerability of pasireotide long-acting release in acromegaly-results from the acromegaly, open-label, multicenter, safety monitoring program for treating patients who have a need to receive medical therapy (ACCESS) study.Endocrine · 2017
   Trial
2. Insights into GLP-1 and insulin secretion mechanisms in pasireotide-induced hyperglycemia highlight effectiveness of Gs-targeting diabetes treatment.Scientific reports · 2025
   Article
3. Medical treatment of Cushing's disease with concurrent diabetes mellitus.Frontiers in endocrinology · 2023
   Review
4. Practical therapeutic approach in the management of diabetes mellitus secondary to Cushing's syndrome, acromegaly and neuroendocrine tumours.Frontiers in endocrinology · 2023
   Review
5. Impairment in insulin secretion without changes in insulin resistance explains hyperglycemia in patients with acromegaly treated with pasireotide LAR.Endocrine connections · 2022
   Article
6. Approach to the Patient With Treatment-resistant Acromegaly.The Journal of clinical endocrinology and metabolism · 2022
   Article
7. Glucose metabolism outcomes in acromegaly patients on treatment with pasireotide-LAR or pasireotide-LAR plus Pegvisomant.Endocrine · 2021
   Article
8. The Interaction of Insulin and Pituitary Hormone Syndromes.Frontiers in endocrinology · 2021
   Review

Corrections and comments

• Comment on
  Effect of pasireotide on glucose- and growth hormone-related biomarkers in patients with inadequately controlled acromegaly.2016

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as